Physician profile
Ayman A Koteish
NPI 1720035272
$349,860.90
in general payments reported to CMS, 2019-2025
17 companies · $63K in 2025
The $63K reported for 2025 was more than what 92% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107K · 2020: $39K · 2021: $37K · 2022: $34K · 2023: $18K · 2024: $53K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Travel and Lodging: $14K · Consulting Fee: $12K · Food and Beverage: $4,397 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,468.50 |
| Travel and Lodging | $13,598.20 |
| Consulting Fee | $12,017.50 |
| Food and Beverage | $4,396.62 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,340.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $145,834.25 | 2019-2025 | Vemlidy, Epclusa |
| Ipsen Biopharmaceuticals, INC | $74,606.07 | 2024-2025 | Iqirvo |
| Abbvie INC. | $52,732.76 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $39,153.65 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $22,175.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Dova Pharmaceuticals | $7,459.64 | 2019 | |
| Shionogi INC | $4,600.84 | 2019-2020 | |
| Eisai INC. | $2,580.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.56 | 2019-2022 | |
| Novo Nordisk INC | $120.19 | 2025 | |
| Medical Device Business Services, INC. | $116.50 | 2019 | |
| Merck Sharp & Dohme LLC | $114.60 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $114.46 | 2024 | Imfinzi |
| Mallinckrodt Hospital Products INC. | $46.74 | 2023 | Terlivaz |
| Intra-Sana Laboratories | $40.69 | 2022-2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Koteish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.